Woodworth Michael H, Carpentieri Cynthia, Sitchenko Kaitlin L, Kraft Colleen S
a Division of Infectious Diseases, Department of Medicine , Emory University School of Medicine , Atlanta , GA , USA.
b Department of Pathology , Emory University Hospital , Atlanta , GA , USA.
Gut Microbes. 2017 May 4;8(3):225-237. doi: 10.1080/19490976.2017.1286006. Epub 2017 Jan 27.
Fecal microbiota transplantation is best understood as an effective and inexpensive therapy for recurrent Clostridium difficile infection but fecal donor selection and screening should be periodically revised. Here, we review current recommendations for selection and screening of fecal donors for fecal microbiota transplantation. We recommend considering diabetes mellitus, prior cardiovascular events, and clinical healthcare exposure as fecal donor exclusion criteria until more is known about the association of these conditions with the human gut microbiome. We review the non-bacterial members of the human gut microbiome, associations of the gut microbiome with colorectal malignancies, the human gut resistome and how these may impact future donor screening recommendations. Collaboration between clinicians, clinical laboratory scientists, industry and regulatory agencies will be critically important for continued improvement in donor selection and screening.
粪便微生物群移植最好被理解为一种治疗复发性艰难梭菌感染的有效且廉价的疗法，但粪便供体的选择和筛查应定期修订。在此，我们回顾了当前粪便微生物群移植粪便供体选择和筛查的建议。我们建议将糖尿病、既往心血管事件和临床医疗暴露作为粪便供体排除标准，直到更多地了解这些情况与人类肠道微生物群的关联。我们回顾了人类肠道微生物群的非细菌成员、肠道微生物群与结直肠癌的关联、人类肠道耐药基因组以及这些因素如何可能影响未来的供体筛查建议。临床医生、临床实验室科学家、行业和监管机构之间的合作对于持续改进供体选择和筛查至关重要。
